SCHOFIELD, Wis., July 11, 2011 (GLOBE NEWSWIRE) -- PuraMed BioScience, Inc. (OTCQB:PMBS) is announcing that leading headache researcher Dr. Roger Cady, MD will be exhibiting a poster presentation of his independent clinical study of PuraMed's non-prescription migraine medication LipiGesic™ M at the 2011 Headache Update Conference being held at Disney's Grand Floridian Resort & Spa in Orlando July 14-17, 2011. The study was recently published online in Headache, a top-tier medical journal of the American Headache Society, and is expected to be published in the printed version shortly.
The 2011 Headache Update meeting is expected to be attended by over 300 primary care providers and specialists, including anesthesia, pain and addiction, internal medicine, OB-GYN, pediatrics, emergency medicine, ENT, neurology, hospitalists and psychiatry, as well as pharmacists and other health care professionals who are involved in the diagnosis and management of headache and chronic pain patients.
"This will be a very important meeting for PuraMed BioScience, Inc. because of the interest elicited by Dr. Cady's recently published independent clinical study of LipiGesic M," said PuraMed BioScience CEO Russell Mitchell. "This is an excellent opportunity for us to introduce and further discuss our product and study with many of the leading headache specialists in the U.S."
The presentation by Dr. Cady will highlight the recent study that reported 64 percent of subjects found pain relief within two hours of taking LipiGesic M. The study concluded that sublingual feverfew/ginger appears safe and effective as a first-line treatment for a population of migraineurs who frequently experience mild headache prior to the onset of moderate to severe headache.
The study was a multi-site, double-blind, placebo-controlled study approved by an independent investigational review board and conducted at three headache centers in the United States. The study, titled "A Double-Blind Placebo-Controlled Pilot Study of Sublingual Feverfew and Ginger (LipiGesic™ M) in the Treatment of Migraine," was conducted by lead investigator Roger K. Cady, MD with the assistance of two additional nationally recognized investigators, Jerome Goldstein, MD, of San Francisco, Calif. and Robert Nett, MD, RPh, of San Antonio, Texas.
Dr. Roger Cady is the founder of Headache Care Center, Clinvest, and Primary Care Education Network. He is a graduate of the Mayo Medical School, and is Board Certified by the American Board of Family Practice. His board certification in Headache Medicine was awarded by the United Council for Neurologic Subspecialties, and he holds a Certificate of Added Qualification through the National Board of Certification in Headache Management. He is a member of multiple medical associations, including the American Medical Association, the National Headache Foundation, the American Headache Society, the American Academy of Pain Management, and the American Academy of Family Physicians. Dr. Cady is best known in the medical community for his pivotal contributions in the field of headache and migraine management. He was the co-recipient of the prestigious Wolff Award in 2000 from the American Headache Society for his research entitled "The Spectrum of Headache". He is well-published and has presented countless lectures and seminars around the world on headache, migraine, and other chronic disorders, and continues to be the principal investigator in numerous multi-center research studies. Dr. Cady currently serves on 12 Advisory Boards and is a member of the Board of Directors for the National Headache Foundation.
About PuraMed BioScience, Inc.:
PuraMed BioScience, Inc. engages in the research, development and marketing of non-prescription medicinal and healthcare products. In addition to its leading product LipiGesic™ M, which provides acute relief from migraine headaches, the Company also has plans to launch LipiGesic™ PM that provides a remedy for insomnia and other sleep disorders as well as LipiGesic™ H for tension-type headaches. For more information on PuraMed, visit the Company website at www.PuraMedBioScience.com/" target="_top" rel="nofollow">www.PuraMedBioScience.com, join the Company's group page on Facebook by searching "PuraMed BioScience" and follow the Company on Twitter at www.twitter.com/puramed" target="_top" rel="nofollow">www.twitter.com/puramed.
Forward Looking Statements: This news release contains forward-looking statements regarding PuraMed BioScience and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.